Please assess the completion status of the following clinical trial:

Trial Title: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease~* ER positive tumor ≥ 10%~* HER2 negative breast cancer by FISH or IHC~* Progression of advanced breast cancer on first or second line endocrine therapy for advanced breast cancer~* Paraffin-embedded tumor available for centralized assessment of biomarkers~* Measurable disease according to RECIST 1.1 (bone only disease is allowed only if measurable).~* Postmenopausal status~* Eastern Cooperative Oncology Group (ECOG) Performance status 0 -2~* Resolution of all acute toxic effects of prior therapy or surgical procedures to CTCAE grade \>1~* Adequate organ function~Exclusion Criteria:~* Unstable brain metastases~* Prior treatment with more than one line of CT or more than two lines of HT advanced breast cancer or any CDK inhibitor~* Current treatment with therapeutic doses of anticoagulant~* Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors / inducers, drugs that are predominantly metabolized by CYP3A with narrow therapeutic indices, drugs with the potential of prolonging QT interval~* Diagnosis of any secondary malignancy within the last 3 years~* Active inflammatory bowel disease or chronic diarrhea~* Known human immunodeficiency virus infection; active hepatitis C, active hepatitis B

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Palbociclib monoterapy
- Arm B (Type: EXPERIMENTAL): Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)

Based on this trial design, predict the completion outcome and termination type (if applicable).